This study demonstrates that metformin treatment significantly increases the sensitively of cisplatin in gastric cancer cells, the increasing appears to be largely dependent to the inhibition of Nrf2 expression and metabolic reprogramming and the activation of oxidative stress and the pathway of p53 and AMPK. This evidence concerns the gene NFE2L2 and gastric cancer.